MedPath

Factors Associated to Success of Hepatitis C Therapy

Completed
Conditions
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Interventions
Registration Number
NCT00514111
Lead Sponsor
UPECLIN HC FM Botucatu Unesp
Brief Summary

The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

Detailed Description

Chronic hepatitis C virus(HVC) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated three million estimated cases to 52 thousand reports. The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • HVC patients that received specific treatment with pegylated-interferon or conventional-interferon, and ribavirin
Exclusion Criteria
  • No HVC infection or treatment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
HVC Patientspegylated-interferon, conventional-interferon, ribavirinHVC patients attended in SAE e HD.
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

SAE e Hospital Dia de Aids

🇧🇷

Botucatu, Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath